BOEHRINGER INGELHEIM

BACKGROUNDER

1. BOEHRINGER INGELHEIM'S COMMITMENT TO ONCOLOGY

Boehringer Ingelheim's oncology research is driven by a passion to advance clinical practice and a determination to improve the lives of patients who are battling cancer. Through scientific innovation and partnerships, the company is focused on discovering and providing novel best-in-class, breakthrough cancer medications that fit the needs of patients, caregivers and healthcare professionals.

With dedicated oncology research facilities in Vienna and immuno-oncology centres in Ridgefield, Connecticut and Biberach, Germany, plus thousands of world class researchers, the commitment to patients and the research community is clear.

2. RESEARCH AND DEVELOPMENT PIPELINE

Boehringer Ingelheim embraces the challenge of developing compounds that fulfil an unmet need in oncology. The company strives to develop treatments that achieve Breakthrough Therapy Designation and have the potential to advance clinical practice.

The oncology pipeline is robust and transformative, with contributions from both unique in-house research and development programmes as well as from strong academic and industry partnerships.

LET'S WORK
ONCOLOGY FROM BOEHRINGER INGELHEIM

Boehringer Ingelheim

3. DRIVING EXCELLENCE IN LUNG CANCER

Boehringer Ingelheim has a clear strategy to become a leader in the field of lung cancer. The company has successfully launched two lung cancer treatments, afatinib* (Giotrif®) and nintedanib** (Vargatef®), which have been widely adopted and established as additions to current clinical practice.

Boehringer Ingelheim has a robust pipeline of oncology compounds, with a number of potential first-in-class lung cancer treatments in development, including cancer immunotherapeutic.

4. PARTNERSHIPS AND COLLABORATIONS

Partnering is a key pillar of Boehringer Ingelheim's oncology strategy, at all stages of research and development, in order to offer cancer treatments that fit the needs of patients, carers and healthcare professionals. Each partner brings a unique offering, perspective and expertise in order to develop new treatments of high therapeutic value.

A large number of collaborations with both academic partners and biotechnology companies are helping to advance Boehringer Ingelheim's search for novel therapeutic concepts, biomarkers, drug candidates and treatment modalities.

These include a research and development partnership with ViraTherapeutics to develop novel cancer treatments based on oncolytic viruses, with an option to acquire the company at a later time point. In addition a strategic collaboration with Sarah Cannon Research Institute (SCRI) that brings together Boehringer Ingelheim's extensive experience in cancer drug development and SCRI's expertise in designing and executing clinical trials of investigational oncology drugs.

Boehringer Ingelheim also have in-licencing partners, including CureVac, clinical development partners, including Eli Lilly and Gilead, and continues to work with patient advocacy groups partners such as The Global Lung Cancer Coalition.

**Afatinib is approved in a number of markets, including the EU, Japan, Taiwan and Canada under the brand name Giotrif®, in the US under the brand name Gilotrif® and in India under the brand name Xovoltib® for use in patients with distinct types of EGFR mutation-positive NSCLC. Afatinib is also approved in the EU, US and other markets for the treatment of patients with advanced SqCC of the lung whose disease has progressed (on or) after treatment with platinum-based chemotherapy. Afatinib is under regulatory review by health authorities in other countries worldwide. Registration conditions differ internationally, please refer to locally approved prescribing information.*
*** Nintedanib is approved in the EU under the brand name Vargatef® for use in combination with docetaxel in adult patients with locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma tumour histology after first-line chemotherapy. Nintedanib is under regulatory review by health authorities in other countries outside the EU. Nintedanib is not approved in other oncology indications.*